Novartis looking for new homes for midphase asthma, eye disease and NASH assets after pipeline review

Novartis has put a trio of midphase drugs up for partnering. After performing its annual portfolio review, the Swiss Big Pharma decided to bring in outside support to drive development of treatments for retinitis pigmentosa, asthma and nonalcoholic steatohepatitis (NASH).